|
|
Molecular pathology and clinical
characteristics of oligodendroglial neoplasms
Walker C, du Plessis DG, Joyce KA, Fildes D,
Gee A, Haylock B, Husband D, Smith T, Broome
J, Warnke PC
JK Douglas Laboratories, Bebington, Wirral, United Kingdom.
carol.walker@ccrt.nhs.uk
To evaluate the role of molecular genetics in the routine clinic, we
investigated allelic imbalance at 1p36, 19q13, 17p13, 10p12-15, and
10q22-26 and p53 mutation in 100 oligodendroglial neoplasms diagnosed
at a single treatment center between 2000 and 2003.
The -1p/-19q genotype, seen in 64, 34, 77,
and 30% of OII, OAII, OIII, and OAIII respectively, was inversely
related to p53 mutation and 17p13 loss.
Genotype was unrelated to tumor location
and could not distinguish high-grade tumors that presented de novo
from those that progressed from a previous lower grade
malignancy.
Presentation with seizures was more common
in cases with the -1p/-19q genotype, and these remained stable for
longer before treatment.
In longitudinal samples, 74% retained
their initial histological differentiation, whereas 29% showed new
genetic alterations, the -1p/-19q genotype being acquired in three
cases.
Loss of 1p36 and 19q13, 17p13, chromosome
10, and p53 mutation were significantly associated with survival from
presentation in Kaplan-Meier analysis (p < 0.01), and loss of 1p36
and 19q13 and loss of 17p13 retained significance in multivariate
analysis.
In this recently diagnosed unselected
series, clinical differences in tumors with and without the -1p/-19q
genotype support a genetic approach to aid diagnosis and
prognostication for oligodendroglial neoplasms.
|
